Novadaq Technologies: Novadaq To Release Third Quarter 2013 Financial Results
The following excerpt is from the company's SEC filing
Toronto, Ontario October 10, 2013 Novadaq® Technologies Inc.
(Novadaq or the Company) (NASDAQ: NVDQ, TSX: NDQ), a developer of clinically-relevant imaging solutions for use in surgical and outpatient wound care procedures, will announce its third quarter 2013 financial results before
the market opening on Tuesday, October 22, 2013.
Novadaq is pleased to invite all interested parties to participate in a conference call, on
October 22 at 8:30 a.m. Eastern Time, during which the results will be discussed.
Those wishing to access the live conference call by telephone
should dial 1-877-407-8031 (within Canada and the United States) or 1-201-689-8031 (international callers) several minutes prior to the beginning of the call. A telephonic replay of the conference call
will be made available until midnight on November 22, 2013 and can be accessed by dialing 1-877-660-6853 (within Canada and the United States) or 1-201-612-7415 (international callers) and entering the conference identification number 100629
The call will be archived for 90 days on the Companys website at http://www.novadaq.com under the Events tab in the
Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaqs website.
professionals with clinically-relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is Novadaqs global mission.
SPY® fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 80
peer-reviewed publications demonstrate that the use of SPY imaging during complex surgery, leads to fewer post-operative complications and lower hospital costs.
SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY
called PINPOINT®, combines the capabilities of SPY Imaging with high definition (HD) visible light visualization offered by conventional endoscopes. LUNA is used to assess
perfusion in patients being treated for non-healing wounds. In August 2013, Novadaq acquired the surgical scintigraphy imaging technology, which is being developed for perioperative imaging of sentinel lymph nodes and tumor margins. Our unique
business model of partnering with market-leading companies to drive adoption of our imaging technology, while building our own commercial infrastructure, is the cornerstone of our corporate strategy for growth.
Certain statements included
in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by
such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaqs current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, the Companys strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial
position, future revenues/results, projected costs, prospects and plans and objectives of management.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings available
at www.sec.gov and www.sedar.com, actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here.
To receive a free e-mail notification whenever Novadaq Technologies Inc
makes a similar move, sign up!